Sybrava PFS 284 mg Injection 1.5 ml 1's is used to lower low-density lipoprotein cholesterol (LDL-C), commonly known as bad cholesterol, in patients with hyperlipidemia. Hyperlipidemia is a condition marked by elevated levels of lipids (fats), such as cholesterol and triglycerides, in the blood, which can increase the risk of heart disease, stroke, and other health complications.

Sybrava PFS 284 mg Injection 1.5 ml 1's contains Inclisiran, a PCSK9 inhibitor monoclonal antibody. It works by blocking PCSK9, a protein that regulates receptors on liver cells responsible for clearing LDL-C from the bloodstream. Inhibiting PCSK9 increases the number of LDL receptors, which lowers LDL-C levels and reduces the risk of atherosclerotic cardiovascular diseases.

A healthcare professional will administer Sybrava PFS 284 mg Injection 1.5 ml 1's. In some cases, this medicine may cause side effects like headache, dizziness, cough, bronchitis, diarrhoea, back pain, pain in a joint, or injection site reactions. The majority of these side effects may not require medical treatment and will subside with time. However, if the side effects persist or worsen, consult a doctor.

Sybrava PFS 284 mg Injection 1.5 ml 1's should not be administered if you are allergic to it. Before receiving the injection, inform your doctor about any allergies, medications, or conditions that may affect your treatment, such as a history of heart, liver, or kidney disorder. Pregnant and breastfeeding women should consult their doctor before receiving Sybrava PFS 284 mg Injection 1.5 ml 1's. Sybrava PFS 284 mg Injection 1.5 ml 1's is not recommended for children below 18 years, as its safety and efficacy have not been established.

A healthcare professional will administer this medicine subcutaneously in the abdomen, thigh, or upper arm. Do not self-administer.

Sybrava PFS 284 mg Injection 1.5 ml 1's effectively reduces LDL cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). Lowering LDL cholesterol helps prevent cholesterol buildup on the arterial walls, thereby reducing the risk of blockages that can restrict blood flow to the heart, brain, and other vital organs. It has minimal interactions with most other cholesterol-lowering medications, making it suitable for use in combination with other treatments.

Inform your doctor if you are allergic to any of the components in Sybrava PFS 284 mg Injection 1.5 ml 1's. If you are pregnant or breastfeeding, consult your doctor before receiving Sybrava PFS 284 mg Injection 1.5 ml 1's. Let your doctor know if you have a history of heart disease, kidney or liver disease, allergic reactions, breathing problems, arthritis, psoriasis, eczema, urinary tract infections or if you have had any recent vaccinations. Sybrava PFS 284 mg Injection 1.5 ml 1's is not recommended for children below 18 years, as its safety and efficacy have not been established.